🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Yonina Murciano-Goroff (Yonina Murciano-Goroff) studies early drug development for #cancer. At #AACR23, she shared new research into how she's using biomarkers and genomic data from MSK-IMPACT® to identify effective treatments for patients.

Honored to be part of this section at #ASCO23 with this stellar group!

#molecular alterations in #nsclc #lcsm more targets more effective therapies #pathologist and #oncologist together against cancer Guilherme Harada

📣Não perca a cobertura que realizaremos no Congresso ESMO® 2023! 🔬Acompanhe nossas redes sociais e site para as principais atualizações sobre o Congresso ESMO® 2023. #MDHealth #Oncologiabrasil #ESMO2023 #Oncologia #news #novidades

What an honor to have you here! Thank you for joining us!

📣Vem aí Agnostic Talks! Nesta primeira sessão, Dr. Guilherme Harada e Dr. Marcelo Corassa comentarão os conceitos abordados nas terapias agnosticadas, trazendo experiências e tendências sobre o assunto.🧪 #MDHealth #OncologiaBrasil #oncologia #terapia

Great presentation by Paola Roa from the Cocco lab about the preclinical activity of zurletrectinib, a novel next-gen TRK inhibitor at the 2023 AACR molecular targets and cancer therapeutics conference in Boston! Emiliano Cocco Sylvester Comprehensive Cancer Center

#ESMO23 Phase II study of cabozantinib in #MET altered (mostly ex14) NSCLC (85% post MET TKI). Cabo is a type II inhibitor. RR 17%, mPFS 6.3m. 67% dose reduction but some very durable responses. Great work Dr. Guilherme Harada Alexander Drilon MD

📣Neste vídeo, Dr. Guilherme Harada, comenta os dados do estudo DESTINY-PanTumor01, que mostrou que T-DXd demonstra boa atividade antitumoral dada boas taxas e sustentação de resposta objetiva. Confira🔽 4et.us/s31eed #MDHealth #OncologiaBrasil #ESMO2023 #oncologia

🚨🚨Wild-type RET amplification represents a potentially targetable subset of cancer. t.ly/sIXtP This report by our stellar med student Malini Gandhi shows these alterations can be seen across cancers and respond to RET inhibition. OncoAlert #LCSM JCO Precision Oncology

Had a great time and thoughtful conversations on the current & future role of ADCs in #NSCLC w/ terrific Brazilian colleagues and friends in San Paolo 🇧🇷. Thanks for hosting Marcelo Corassa, MD. João Alessi, MD Guilherme Harada Gustavo Schvartsman Helano Freitas Ricardo Zylberberg Luiz Araujo #DASA

It is a pleasure to introduce to you the new board and steering committee of the LACOG Lung Group. The new formation of the group will run from 2023 to 2025, and will continue with the goal of developing new clinical and epidemiological studies with a focus on lung tumors.

🧐Impacto das variantes de ALK e co-mutações nos padrões de resistência adquirida e sobrevida. Mutações em TP53 e perda de CDKN2A/B foram as mais frequentes e associadas com pior SG. EML4-ALK v3 foi associada com pior SLP mas não com SG.Guilherme Harada pubmed.ncbi.nlm.nih.gov/38407352/

Glad to share our paper just published in Cancer Discovery that characterizes mutations in the MET kinase domain in lung cancer and other malignancies from a clinical, preclinical and structural point of view. doi.org/10.1158/2159-8…

In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. Yonina Murciano-Goroff Alexia Iasonos

It has been a long journey BUT now I Comfortable wearing yellow I stage. Dare to be different, dare to be YOU! #LatinasInMedicine Fumiko Ladd Chino, MD, FASCO

#MET kinase domain mutations can drive off-target resistance to targeted therapies in #NSCLC. In this study led by #ShesiruNakazawa & Federica Pecci, we demonstrate how combinations w/ MET TKI can overcome this resistance. JTO & JTO CRR OncoAlert IASLC jto.org/article/S1556-…

Phase II study of cabozantinib in #MET altered lung cancer JTO & JTO CRR from Guilherme Harada Alexander Drilon MD (n=28). RR 20% and 4/5 responses were previously treated with type I MET TKI. PFS 4.5m, OS 7.2m. jtocrr.org/article/S2666-…

How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, Clarissa Mathias moderates a discussion with Guilherme Harada and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC. 🎧 Listen now: bit.ly/VTBport